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1. Introduction 
Diseases of the liver are becoming increasingly recognized due to their elevated prevalence 
and their impact on patients’ daily life (Younossi,1998; Armstrong, 2000). Besides, in recent 
years enormous progress in diagnosis and therapeutics has been made. Currently, liver 
transplantation is the treatment of choice in selected patients for acute and chronic liver 
failure (Tomé, 2008; Desai, 2008). Liver transplantation has shown that it improves both 
survival and perceived changes of quality of life (Tomé, 2008; Duffy, 2010). Survival after 
liver transplantation is excellent, both in the short and long term. Patient survival rates of 
approximately 85% after the first year and 75% five years after transplantation have been 
reported in the European Liver Transplant Registry (www.eltr.org). 
Quality of life (QOL) is a broad concept which includes all aspects of life such as where and 
how one lives and the role he/she plays in society (Bergner, 1989). We have to consider that 
QOL will also be affected by factors such as interactions with the environment, previous 
experiences, cultural background, life expectancy, family life, social interactions, present 
circumstances; financial situation, housing and job satisfaction, which are difficult to 
incorporate in research ( Sanders, 2008; Flamme, 2008).  
QOL is a complex concept involving patient’s perception of his/her ability to perform 
functions such as work, but also comprises the physical effects of the illness and concomitant 
psychological conditions, anxiety, depression, stigma and feeling of hopelessness (Gutteling, 
2007; Cordoba, 2003). Other related issues are studied such as sexual problems, relationships 
with his/her family, friends and the healthcare team (Ware, 1992; Carver, 2005; Day, 2009).  
The present review focuses on relevant patient-reported outcomes such as self-perceived 
symptoms (some are related to immunosuppressor drugs), medication adherence and long 
term HRQOL (Health Related Quality of Life) after liver transplant (Osterberg, 2005). In our 
opinion, although these are interrelated issues we will consider here the most recent 
development of HRQOL in advanced liver disease and transplantation (Unal, 2001). 
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There is some doubt as to what differentiates HRQOL and QOL. Some concepts that can be 
encapsulated under the term QOL include social functioning, emotional well-being, role 
functioning, cognitive functioning, sleep problems, sexual functioning, vitality/energy, 
pain, life satisfaction, body image and general perceptions of health (Table 1) (Borgaonkar, 
2000; van den Plas, 2003). In this chapter we will discuss HRQOL because in clinical practice 
both concepts HRQOL and QOL are used as equivalents, especially for patients with severe 
disease.  
Due to the multidimensionality of HRQOL, it is not possible to measure every dimension 
simultaneously, therefore a more limited and focused assessment should be undertaken. In 
patients with chronic diseases such as advanced liver disease, QOL is based on health 
parameters, and not on more general factors such as socioeconomic status or housing 
conditions since these are often considered as not having any relevance to their medical 
concerns. However, some problems related to finances, corporal image or specific 
architectural needs are contemplated in relation to some medical conditions as it is done for 
the study of QOL in oncological patients using specific tools (Roila & Cortesi, 2001; Gangeri, 
2007).  
Leisure and recreation, Mobility and self-care, Travel, Walking, Food/drink, Running, 
Visit friends’ homes, Climbing, Vacation, Eating, Nearnes sto toilet facilities, Grooming, 
Hobbies and sports, Physical endurance, Relationships, Emotional, Intimacy and sexual 
function, Anger, Body image, Embarrassment, Understanding from others, Anxiety, Coping 
and support, Irritability, Relations with children and extended family, Happiness, 
Friendships, Worries or fears, Pain and discomfort, Ability to relax, Chest pain, Frustration, 
Abdominal pain, Depression/sadness, Abdominal cramps, Satisfaction, Abdominal 
discomfort, Job-education, Rectal pain, Satisfaction, Back pain, Attendance, Headaches, 
Concentration, Extra intestinal pain, Task completion, Joint pain, Achievement/promotion, 
Well being, Financial reward, Energy, Treatment, Fatigue, Efficacy, Sleep, Adverse effects, 
Self-control 
Table 1. Problems, issues and domains of health related quality of ife (HRQOL) studied by 
questionnaires (Borgaonkar, 2000.) 
2. Methods for studying QOL 
In practice most research has measured HRQOL as a multi-dimensional construct, 
instruments used to measure it must have at least three core domains: physical, 
psychological and social (Unal, 2001; Drent, 2009). Broadly speaking QOL measures can be 
divided into two categories: generic or condition-specific (Patrick, 1989; van den Plas, 2003): 
2.1 Generic questionnaires 
Generic questionnaires are comprehensive and they can apply to different patient 
populations, allowing comparisons between different diseases. These generic measures have 
the advantage that the obtained scores can be compared with the scores of other patient 
populations or with a healthy control group, stratified by age and gender. A recognized 
disadvantage is that generic instruments are not designed to identify disease specific  
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domains which may be important when we want to establish whether clinical changes have 
occurred and whether or not they are significant (Jay, 2009). 
In the last few years one of the major clinical concerns has been to obtain a good level of 
QOL after therapeutic interventions. It is therefore crucial to study QOL by asking 
questions which are relevant to the patients (Hays, 2000). The concept of patient reported 
outcome is related to an in depth study of the meaningful changes perceived by the 
patients (Gill, 1994).  
A patient-reported outcome (PRO) can be defined as “any outcome based on data provided 
by patients or by patient proxy as opposed to data provided from other sources”. PROs that 
are of importance to liver transplant patients are: symptom experience, medication 
adherence and HRQOL. The effectiveness of treatment after organ transplantation depends 
both on the skills of the health care team and on the life-long, active cooperation of the 
patient. (Bayliss,1999). 
The clinical information provided to the patient and caregivers about long-term side effects 
of drugs, and of the possibility of developing recurrent or “de novo” disease is essential 
(Nickel, 2002). This means that transplantation will have an impact on the daily life and the 
well-being of the patient and will remain as a chronic condition (Stewart, 1989). The three 
most commonly used generic HRQOL instruments are: the Nottingham Health Profile 
(NHP), the Medical Outcomes Study Short Form-36 (SF-36) and the Sickness Impact Profile 
(SIP). (Table 2) (Coons, 2000; Hunt, 1980; de Bruin, 1992; Bergner, 1976). All three 
instruments have sufficient psychometric properties.  
The Medical Outcomes Study 36-item Short Form Health Survey (SF-36), consists of 36 items 
which measure eight scales: physical functioning (PF), (10 items), role limitations due to 
physical problems (RP), (4 items), bodily pain (BP), (2 items), general health (GH), (5 items), 
vitality (VT), (4 items), social functioning (SF), (2 items), role limitations due to emotional 
problems (RE), (3 items), and mental health (MH) (5 items). On the basis of these separate 
subscales, component summary scores can be calculated to provide a global measure of 
physical (Physical Component Summary score, PCS) and mental functioning (Mental 
Component Summary score, MCS), respectively. The scale scores range from 0 to 100, with 
higher scores indicating a better health status. The PCS and MCS have been standardized on 
the basis of a normative general population of different countries, with the mean set at 50 
(SD 10) (Guyatt,1993) The SF-36 is currently the most used instrument worldwide, and a 
shorter version is available (SF-12) (Bruns, 2010).  
2.2 Nottingham Health Profile (NHP) 
(1) Part I: 38 questions in 6 subareas, with each question assigned a weighted value; the sum 
of all weighted values in a given subarea adds up to 100, (Hunt, 1985), 
• Energy level (EL): 3,  
• Pain (P): 8,  
• Emotional reaction (ER): 9,  
• Sleep (S): 5,  
• Social isolation (SI): 5,  
• Physical abilities (PA): 8 
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(2) Part II: Seven daily life areas that can cause problems in your present state of health:  
• Work (i.e. paid employment);  
• Looking after the home (cleaning & cooking, repairs, odd jobs around the home, etc.);  
• Social life (going out, seeing friends, going to the movies, etc.);  
• Home life (i.e. relationships with other people in your home);  
• Sex life;  
• Interests and hobbies (sports, arts and crafts, do-it-yourself, etc.);  
• Vacations (summer or winter vacations, weekends away, etc.) (Hunt,1980). 
Generic 
Tests 
Nottingham Health 
Profile (NHP) 
Medical Outcomes Study 
Form (SF-36) 
Sickness Impact Profile 
(SIP) 
Authors Hunt et al. 1980, 1985 Ware et al. 1992 
Brazier et al. 1992 
(Validation) 
Bergner et al. 1981 
Number of 
items 
38 36 136 
Number of 
subscales 
6 8 12 
Total score No Yes, -Emotional role** 
-Physical role** 
Yes 
Reliability IC:Cronbach alpha: 0.70-
0.85 
TRT.r: 0.75-0.88 
IC: Cronbach alpha > 0.84 
TRT.r: 0.60-0.81 
IC:Cronbach alpha: 0.94 
TRT.r: 0.87-0.97 
Validity* CV: Ill vs healthy people
DV: Between groups 
with various health 
statuses 
Conv. V: correlations 
between four comparable 
dimensions of SF-36 and 
NHP were high 
DV: Correlations between 
non comparable 
dimensions of SF-36 and 
NHP were low 
Conv. V: E.g. Activity of 
daily living.  
Index:r:0.55-0.61 
DV: E.g. explained 
variance of Speech 
Pathology Ratings 
Clinical and Descriptive 
validity  
Subscales/ 
domains 
- Energy 
- Pain 
- Emotional reactions
- Sleep,  
- Social isolation 
- Physical mobility 
- Seven activity of 
daily living 
questions  
- Physical functioning 
- Role limitations due 
to physical problems 
- Bodily pain,  
- General health 
- Vitality,  
- Social function 
- Role limitations due 
to emotional problem 
- Mental health 
 
IC: Internal consistency; TRT: Test Re-test reliability; CV: Construct validity; Conv. V: Convergent 
validity; DV: Discriminant validity. 
*All reported validities have been established 
** Mental component score and physical component score  
Table 2. Most commonly used generic HRQOL instruments 
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2.3 Disease-specific questionnaires have been developed to be valid only for one 
specific condition 
A review of QOL instruments used in liver transplantation has been published recently (Jay, 
2009). In this article, among others, authors discussed existing QOL instruments with its 
individual strengths and limitations. 
In this chapter we will discuss four specific questionnaires, that have been designed for 
CLD: (Table 3.) (Gutteling, 2007). In table 3 we present the two more frequently used 
questionnaires. 
Specific HRQOL 
instruments 
Chronic Liver Disease 
Questionnaire (CLDQ) 
Liver Disease Quality of Life 
Questionnaire (LDQOL)** 
 
Authors Younossi et al.1999 Gralnek et al.2000 
Number of items 29 101 
Number of subscales 6 20 
Total score Yes No 
Reliability TRT: IC: 0.59 IC: 
Cronbach alpha> 0.70 
1 subscale alpha:0.62 
 
Validity* CV: Worse CLDQ scores 
with increased disease 
severity  
CV: Worse LDQOL scores with 
increased disease severity for all 
subscales 
 
Subscales - Fatigue 
- Activity 
- Emotional function 
- Abdominal 
symptoms 
- Systemic symptoms 
- Worry 
8 subscales of the SF-36 adding 
specific scales: 
- CLD-related symptoms 
- CLD-related effects on 
activities of daily living,  
- Concentration,  
- Memory,  
- Sexual functioning 
- Sexual problems,  
- Sleep,  
- Loneliness,  
- Hopelessness,  
- Qual.of social interaction,  
- Health distress 
- Self-perceived stigma of CLD 
 
IC: Internal consistency; TRT: Test Re-test reliability; CV: Construct validity; Conv. V: Convergent 
validity; DV: Discriminant validity; CLD: Chronic Liver Disease. 
*All reported validities have been established 
**A prospectively validated Short Version of LDQOL has been published (Kanwal, 2008) 
Table 3. The two most commonly used specific HRQOL instruments for candidates or 
recipients of liver transplantation (Jay, 2009) 
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2.3.1 Hepatitis quality of life questionnaire (HQLQ) (Bayliss, 1998) 
In addition to a standard SF-36 generic core, comprised of eight scales, HQLQ contains five 
generic items consisting of two questions for the social functioning scale and one question 
each for physical role, emotional role and vitality scales to augment existing SF-36 scales. 
HQLQ is addressed only to hepatitis C patients. This instrument will be useful in studies of 
health outcome among patients with chronic hepatitis C, a condition whose health burden 
appears to have been underestimated in studies to date. 
2.3.2 Chronic Liver Disease Questionnaire (CLDQ) (Younossi, 1999) 
This instrument introduced in 2000, has two parts: the generic SF-36 and six specific scales, 
with a number of individual items: abdominal symptoms, fatigue, systemic symptoms, 
activity, emotional function and worry. These items were selected based on 60 chronic liver 
disease patients, 20 liver experts and a review of the literature. Younossi et al. established 
construct validity according to significant differences in CLDQ scores according to Child’s 
classification. 
2.3.3 Liver Disease Quality of Life Questionnaire (LDQOL) (Gralnek, 2000) 
LDQOL is a targeted instrument which incorporates the generic SF-36 as well as 12 disease-
targeted multi-item scales: liver disease-related symptoms, liver disease-related effects on 
activities of daily living, concentration, memory, sexual functioning, sexual problems, sleep, 
loneliness, hopelessness, quality of social interaction, health distress, and self-perceived 
stigma of liver disease. This questionnaire was designed for patients with liver disease, such 
as transplant candidates or liver transplant recipients. Gralnek et al., established the validity 
of this instrument for measuring QOL in patients with chronic liver disease in a multi-center 
study of patients referred for liver transplant evaluation. More recently a prospective 
validation of a short form version of the LDQOL including 36 targeted items representing 
nine domains in addition to the SF-36 has been published (Kanwal, 2008). 
The LDQOL was published in 2000, but has only been introduced to clinics recently and 
some studies have been published (Dias Teixeira, 2005; Kim, 2007; Gotardo, 2008; Casanovas 
2010;). 
2.3.4 National Institutes of Diabetes and Digestive and Kidney (NIDDK) 
The Liver Transplant Data Base (NIDDK-LTD), (Belle, 1997) which was developed from 
standardized instruments it is a QOL questionnaire for adults, which includes both physical 
and mental domains and specific areas. Unlike the previous specific instruments, it has not 
been developed in other cultures.  
2.4 Complementary QOL indexes 
Some complementary QOL indexes and questionnaires may allow implementation research. 
The opinion of several authors, such as Jay et al. however, is that, the lack of a gold-standard 
QOL instrument for liver transplant recipients is an impediment to cross-study comparisons. 
Depending on the objective of the study or the target population, complementary 
questionnaires should be used, since other areas may be affected in advanced liver disease 
(Foster, 1998; Dwigt, 2000; Gutteling, 2006). 
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2.4.1 Fatigue Impact Scale (FIS) (Fisk,1994; Hassoun, 2002; Jones, 2009) 
FIS is a validated questionnaire for assessing fatigue. It is used in many chronic conditions. 
The multidimensional assessment of fatigue is complicated by the interrelation of its 
multiple causes and effects. A significant proportion of liver patients suffer fatigue, even 
patients with non advanced disease. Fatigued patients have more sleep problems and higher 
depression scores than non-fatigued patients (Poynard, 2002). Self rated depression is 
present in 28% of fatigued patients compared with 4% of non-fatigued patients. Long term 
fatigue affects 68% of the patients with PBC but it is not related to the severity of their liver 
disease (Morana, 2009).  
2.4.2 Beck’s Depression Inventory (BDI) (Beck, 1961) 
Beck’s Depression Inventory is a 21-item self-report rating inventory measuring characteristic 
attitudes and symptoms of depression. The total score ranges between 0 and 63; scores 
below 14 are considered normal, scores from 14 to19 indicate mild to moderate depression, 
scores from 20 to 28, moderate to severe depression, and scores higher than 28 are indicative 
of severe depression. This questionnaire is regularly used as a complementary measure. 
2.4.3 State-Trait Anxiety Inventory (STAI) (Guillén-Riquelme, 2011) 
Since physical symptoms associated with end-stage liver disease, such as poor appetite and 
fatigue, are also associated with depression, the scores of liver transplant candidates in three 
separate areas, somatic, cognitive, and affective, have to be computed. Therefore, the State-
Trait Anxiety Inventory is one of the most frequently used instruments for measuring 
anxiety in adults and has been demonstarted to be valid and reliable. It consists of 20 
statements that assess how respondents feel “generally.” Scores can vary between 20 and 80, 
with higher scores indicating more anxiety. 
2.4.4 Cognitive Operations Preference Enquiry-Easy (COPE-EASY) (Francis, 2009) 
Independently of important cultural differences and health systems, coping with chronic 
diseases is crucial for patients and caregivers (Saab, 2011). The Coping Operations 
Preference Enquiry-Easy (COPE-Easy) consists of 32 questions, incorporating 15 distinct 
coping strategies that can be grouped into three subscales: active problem focused coping, 
avoidant coping and seeking social support (Gutteling 2007). 
3. Factors influencing QOL measurements: Age, gender, expectancies, cause 
of liver disease, differences between men and women and mode of 
administration  
Persons with severe liver disease often have a poor quality of life before liver 
transplantation (van den Plas, 2003). This poor quality of life is related to chronic disease 
and a decline in health caused by poor liver function (Marchesini, 2001). Medical treatments 
may be of some help in limiting symphtoms in cirrhosis and its complications (Hussain, 
2001; Younossi, 2001; Girgrah, 2003; Gutteling, 2008). However, a more complete return of 
quality of life and health must usually wait until after recovery from a successful liver 
transplantation procedure (Castaldo, 2009). In addition, cross-cultural issues have to take 
into account (Hunt, 1986). 
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Currently, liver transplantation is the treatment of choice in selected cases of acute and 
chronic liver failure and HRQOL reached is in general satisfactory, although below the level 
of the general population (Cleemput, 2007). Balanced results have been measured one year 
post- transplant (Takinella, 2010). Results, however, must be interpreted with caution as 
QOL improvements may have been overstated due to variables such as selection bias, 
exclusion of severely ill and deceased patients, too many short-term studies and suboptimal 
methodology (Younossi, 1998). 
In the studies published about QOL after liver transplantation in the nineties, only generic 
instruments were used (Levy, 1995). It is only recently that QOL data have been obtained 
through specific liver disease questionnaires (Jay, 2009). We will mention some studies that 
have identified factors known to enhance QOL. 
For example, patients with a history of alcoholism or who were regular drug users can be 
accepted in a transplant program only, after rehabilitation (Lucey, 2002; Gangeri, 2002). 
However, some studies observed that they have a greater incidence of psychiatric disease or 
psychological disorders which are responsible for a reduction in their QOL (Dew, 2000; 
2001). Recent publications have addressed this problem, as a transplant candidates, alcoholic 
patients may be considered as a transplant candidates after psychiatric assessment. The 
detection of urinary ethylglucuronide allows the detection of alcohol consumption in 
alcoholic liver disease patients awaiting liver transplantation, (Erim, 2007), although fully 
consensued recommendations have not been achieved, the general recommendation is to 
dedicate more time assessing patients and increasing communication within the 
multidisciplinary transplant team (Kotlyar, 2008). 
The differences in QOL between male and female patients continue to be a subject of 
research (Cowling, 2004; Lowry, 2010). QOL assessed gender differences have been detected 
in chronic illnesses: e.g. women scoring lower levels of QOL (Vazquez, 2004). The same 
results were obtained when assessing chronic HCV-related liver diseases. Teixeira et al. 
2006, using the SF-36 or the specific LDQOL instrument found statistically significant 
differences. They tested differences in the following domains: liver disease symptoms, 
concentration, memory, worrying about the disease and sexual problems. Russell et al 2008, 
with the administration of, SF-36 the Center for Epidemiologic Studies Depression Scale 
(CES-D), and Beck Anxiety Inventory Scale, observed similar results. 
Gifford. et al, in Australia, using the generic instrument SF-12, observed a reduction of QOL 
for women between 15 and 71 years of age (Gifford, 2003). While the reasons for the lower 
QOL in women have not yet been clearly defined, the findings indicate that social and 
cultural problems associated to the disease may be implicated. Interestingly, these 
observations have been repeated for different chronic conditions, backgrounds or 
geographic origins. In Spain this has been corroborated by Ferrer et al using the CLDQ 
(Ferrer, 2006 ). 
The main concern among men is related to their professional activities; they are worried 
about not being able to provide for their families. Although there are different circumstances 
implicated in symptoms or in alteration in the QOL, the way that patients react to the 
diagnosis or treatments and its consequences are different in both genres (Gifford, 2005). 
In our experience in the Liver Transplant Unit, we observed, using the generic NHP that 
three months after liver transplant women were scoring higher than men, but after six 
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months men were improving progressively whereas women were not, not correlating with 
clinical results (data not published). These facts may corroborate the usual role of women in 
family life. 
The weight of the stigma felt by liver disease sufferers in the past is still present nowadays 
(Scambler, 1998; 2009; Zickmund, 2004). Stigma is defined as the opinion of a dominant 
group with a preformed judgement about attitudes or situations considered socially 
unacceptable. Stigma is found in all levels of society (Zickmund, 2003). 
One explanation is that drug use, a risk factor for AIDS and chronic HCV-related liver 
disease, projects a negative image of these diseases (Kanwal, 2005). In the past, before the 
discovery of the hepatitis C virus in 1989, this situation was observed in cirrhosis patients 
who, despite not being drinkers, were always asked about their drinking habits and were 
sometimes labelled as alcoholics. Another reason is that people living with a carrier are 
afraid of being infected ( Marcellin, 2007). 
Women have reported experiencing greater stigma than men. The presence of this stigma 
can affect self-esteem and cause alteration in the QOL (Strauss, 2006). 
The pre-transplant physician/patient relationship and the coordination with other members 
of the transplantation team are vital. At this stage, the medical information that patients 
receive and the attitudes of the medical team is highly significant (Cordoba, 2003; 
Zickmund, 2004; Flamme, 2008). Knowing about experiences of other patients with the same 
health problems is also positive. Information supplied to the patient and his/her family 
members as well as psychological and social support induces behavioural changes, which 
may be reflected in an improved physiological process (van der Plas, 2003). 
Realizing that social and/or psychological factors play a significant role in patients’ 
HRQOL, transplant teams could take advantage of information collected so far and 
implement new programs (Rodger, 1999; Pieber, 2006; van den Berg, 2006; DiMartini, 2011.) 
Mode of 
administration 
Strengths Weaknesses 
Self Minimal resources required Greater likelihood of low 
response rate 
Interviewer Maximizes response rate. 
Few, if any, missing items 
Requires many resources 
training of interviewers 
May diminish willingness to 
acknowledge problems 
Limits format of instrument 
Surrogate Responder Reduces stress for target group 
(very sick or elderly) 
Perceptions of surrogate 
may differ from target 
group 
Telephone Few, if any, missing items 
Minimizes errors of 
misunderstanding 
Less resource intensive than 
Interviewer administered mode 
Requires resources training 
of interviewers 
Table 4. Modes of administration of questionnaires of HRQOL (Hays, 2009) 
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Effects on the properties of questionnaires of HRQOL related to the mode of administration 
have been studied (Table 4) (Hays, 2009; Gundy, 2010). Significant differences were detected 
in measurements –after adjustment- researchers found that, for the Emotional Functioning 
(EF) scale, patients who had completed the written questionnaire at home had significantly 
lower levels of (EF) compared to those interviewed over the telephone. 
Child-Turcotte-Pugh (CTP), Prognosis of liver disease. 
(CTP A = 5-6 p, CTP B = 7-9 p, CTP C = 10-15 p)  
 
1 point each 2 points each 3 points each 
Ascites None Controlled  Poor control 
Encephalopathy None Grade I-II Grade III-IV 
Total bilirubin, µmol/L (normal = 17.1 µmol/L) < 34 34 – 50 > 50 
Albumin, g/L >3.5 g/dL) 2.5-3.5 g/dL < 2.5 g/dL 
INR < 1.7 1.7–2.2 >2.2 
Table 5. Scoring severity of liver disease MELD (Malinchoc, 2000; Kamath, 2001) and Child-
Pugh (Pugh, 1973). MELD score was developed to determine the severity of liver disease 
based on the patient’s serum bilirubin, serum creatinine, and the international normalized 
ration (INR).It has been proposed to replace the Child-Turcotte-Pugh (CTP) score as a “more 
objective” measure of chronic liver disease severity 
4. HRQOL in patients with chronic liver disease is not associated with 
disease severity as measured by MELD (Model for End-stage Liver Disease) 
score 
Liver transplant is indicated in selected patients with advanced liver disease in which  
other therapeutic measures have failed or are not possible, and with no absolute 
contraindications for this procedure. (Consensus Document of the Spanish Society of Liver 
Transplant, 2009).  
Some type of balance between need and utility has to be considered, meaning that we 
should be cautious with patients with a very severe clinical prognosis when taking 
advantage of a scarce resource, a liver graft. In our opinion, ideally, there should be a 
balance between the subjective perception of health by the patient, friends and close family 
and the clinical severity of the disease based on medical data when deciding on when to do 
the transplant. 
However, some difficulties have to be taken into account. Clinicians base their decisions on 
objective measures, such as analysis and image tests for clinical diagnosis and treatment but 
the moment of transplant also depends on the waiting list and the feasibility of a suitable 
donor. Ideally, it would be desirable to consider both biological objective measures and 
more subjective measures, such as HRQOL (Kanwal, 2004). 
HRQOL in chronic liver patients has been shown to be impaired in numerous studies. 
Gutteling et al. 2006, studied the impact of physical and psychosocial determinants on a 
weighted score of HRQOL in patients with chronic liver disease. They showed that HRQOL 
was related to disease severity and joint pain. Also depression, decreased appetite and 
fatigue were strongly related to HRQOL. In hepatitis C patients, fatigue and depression 
were powerful determinants of HRQOL (Strauss, 2006). Patients with cirrhosis who had a  
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higher Child-Pugh score (measuring disease severity) presented symptoms such as muscle 
cramps, pruritus, and fatigue (Marchesini, 2001), significant factors relating to QOL. Co-
morbid conditions and the duration of disease have not shown in the majority of studies a 
significant relationship with QOL in these patients. However, the relationship between 
psychological distress, symptoms and QOL is less known. 
Some authors, studying the association between HRQOL and survival in patients with 
cirrhosis, showed that the relation between HRQOL and survival was MELD (Model of En-
Stage Liver Disease) independent (Kanwal, 2004; Saab, 2005). Kanwal et al., found that 
higher baseline HRQOL predicted lower mortality (Kanwal, 2009). Specifically, for each 1-
point increase in HRQOL, there was a 4% decrease in mortality. Both social relations and 
support have proved to be favourable predictors.  
Considering that HRQOL has been recognized as an important outcome in chronic liver 
diseases, and clearly determined by disease severity, some changes might be applied in the 
clinical practice. For example, it could be useful to develop a form of intervention aimed at 
improving adaptation to the more frequently identified symptoms and to implement the use 
of a comprehensive assessment of QOL in the evolution of chronic liver disease patients 
with the aim of better clinical management. 
However, in everyday practice, the instruments evaluating QOL in liver disease are rarely 
used due to lack of time and resource constraints (Sanders, 1998; Gutteling, 2007). Some 
doctors, having different priorities, are hesitant to implement this issue. MELD is being used 
to prioritize patients for liver transplantation, with the purpose of limiting mortality in 
patients on the waiting list (Wiesner, 2003). There are paucity of data evaluating associations 
between MELD score and patient-centered outcomes (HRQOL). Kanwal et al. in 2004 
publication “Does Model for End-stage Liver Disease (MELD) predict HRQOL in patients 
with advanced chronic liver disease?” explore these associations. Their research on 
correlations between MELD/CTP and patient-centered outcomes evidenced that in persons 
with advanced chronic liver disease, MELD score predicts patient self-rated severity of liver 
disease symptoms, but fails to predict disability days and the more global outcome of 
HRQOL (Kanwal, 2004).  
CTP score may be a better proxy measure than MELD, due to being based on clinical data 
and is more patient centered disease in persons with decompensated chronic liver disease 
(Saab, 2005). Both hepatic encephalopathy and ascites, which can affect quality of life, are 
not part of the MELD score. Furthermore, the MELD score has not been correlated with the 
severity of ascites and hepatic encephalopathy. Thus, liver disease severity assessed by the 
MELD score may no longer correlate with quality of life. (Saab, 2005) (Table 5). 
MELD score allows prioritizing patients on the waiting list, putting the “sickest first” 
(Schaffer, 2003). However, we have to take into account that the MELD score does not 
always adequately reflect disease severity and prognosis (Frost, 2002). In patients with 
fulminant hepatic failure, metabolic disease, hepatocellular carcinoma, refractory ascites, 
hepato pulmonary syndrome etc. MELD does not apply (Schaffer, 2003). 
Nowadays, although one of the most used disease severity indices is MELD score, it is not 
associated with HRQOL. Several patients with decompensated liver disease do not have a 
high enough MELD score, so we should examine possible causes of the present situation 
and justify and validate other specific instruments or formulas. 
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5. Does etiology of the liver disease appear to influence individual’s HRQOL? 
Issues concerning Acute Liver Disease vs. Chronic Liver Disease 
Pretransplantation HRQOL scores are affected by the etiology of liver cirrhosis, therefore 
it is important the knowledge of the impact of a particular disease. Patients with 
hepatocellular and cholestatic etiologies have higher HRQOL scores than alcohol or viral 
hepatitis patients (Bianchi, 2003; Steel, 2007). Although the individual’s perception of 
his/her state of health is crucial, different etiologies may identify some of the 
characteristics of the components of QOL in liver diseases (Krasnoff,2005). In general 
terms, younger and male people perceive a better QOL compared to older and women 
patients (Painter, 2001). 
In early stages, liver disease patients show few or non-specific symptoms, therefore 
reporting insignificant effects on HRQOL. As the disease progresses to cirrhosis and 
complications arise (ascites, muscle cramps, fatigue etc.) individuals report noteworthy 
effects on HRQOL (Gutteling, 2006; Björnsson, 2009). In patients with advanced disease the 
etiology of the liver disease does not seem to influence patients’ ratings. Although in earlier 
cases of chronic cholestatic liver disease significant pruritus and fatigue may have a 
significant impairment of HRQOL (Poupon, 2004). These symptoms that may also be 
observed in chronic hepatitis C may not be present in those with other forms of chronic liver 
disease such as chronic hepatitis B or iron overload (Lam, 2009). 
We will explore the most important issues that have been developed in the last few years 
(Jay, 2009). Some determinants of HRQOL are derived from specific symptoms and concerns 
of liver diseases, but a generic HRQOL test is unable to measure them (Gutteling, 2007; 
Kotlyar, 2008). Examples of some specific problems observed in advanced liver disease are: 
sleep related problems, sleep pattern changes, stigma of liver disease, symptoms and effects 
of liver disease and their treatments (Holzner, 2001). 
5.1 Issues related to HRQOL in hepatitis C and hepatitis B 
Patients with chronic hepatitis C assessed by the SF-36 show diverse and non specific 
symptoms (fatigue, anorexia, weight loss, abdominal distress…) and usually have 
significant reductions in their SF-36 scores for all of the scales (both mental and physical 
components) (Dwigt, 1998; Foster, 2000; Strauss, 2006) .  
Patients with chronic hepatitis B virus (HBV) infection show a reduction in the SF-36 scores 
that assessed mental functions, but they have no reduction in the scores that measured 
physical symptoms, indicating that the symptoms associated with chronic HCV infection are 
qualitatively different to those associated with chronic HBV infection (Curry, 2004; Spiegel, 
2005; Lam, 2009). 
Patients with chronic HCV infection who had used intravenous drugs in the past had the 
greatest impairment in QOL scores, but the reduction in QOL scores was still found in 
patients who had never used drugs (Weissman, 1980; Fowler 1980). The reduction in QOL 
could not be attributed to the degree of liver inflammation or to the mode of acquisition of 
the infection. Recent studies have demonstrated through cerebral magnetic resonance 
images of abnormal cerebral metabolism and cognitive impairments in patients with chronic 
hepatitis C ( Hilsabeck, 2002; Forton, 2008; Bokemeyer, 2011) 
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5.2 Hepatocellular Carcinoma (HCC)  
Development of a malignant tumour might occur in a cirrhotic liver that can have a 
preserved liver function. For this reason, clinical guidelines recommend screening 
surveillance programs in every cirrhotic patient in order to detect possible tumours in early 
stages to assure treatment efficacy (Ruppert, 2010). Owing to recent advances in early stage 
liver tumour diagnosis, presumably, these patients do not have specific symptoms and their 
perceived HRQOL is perhaps stable, but due to the little research available in this area the 
result for the moment remains uncertain (Kotlyar, 2006; Steel, 2007). 
Indications for orthotopic liver transplantation according to the European Liver Transplant 
Registry (2008), are the following. Virus related indication in 38%; Alcoholic liver disease 
(ALD) related indication in 33%, and 4% had combined aetiology of ALD and hepatitis C 
and B. (Varma, 2010) 
We could assume that at the time of diagnosis of the HCC, patients may suffer distress and 
be disturbed by the prospect of a therapeutical intervention such as a possible liver 
transplant. If the HCC is diagnosed at an early stage the prognosis is good but the patient is 
not adapted to the disease as is the case in a chronic patient (Gangeri, 2007; Castaldo, 2009; 
Crone, 2010). After transplant they might have recurrent viral hepatitis which worsens the 
clinical situation and even the prognosis (Bownik, 2010). New approaches for the 
prophylaxis of recurrent hepatitis C are under evaluation but whether this treatment will 
influence the severity of liver disease or the outcome of recurrence is still unknown.  
5.3 Alcoholic Liver Disease (ALD) 
Patient selection for liver transplantation has always been a demanding responsibility for 
transplantation teams and professionals. In alcoholic liver disease patients, issues related to 
liver transplantation have remained unresolved despite the convincing reports of similar 
survival post transplant in selected ALD patients, compared to those who received 
transplant for other indications (Roberts, 2004). 
A period of abstinence is recommended for alcoholics before being considered possible 
candidates for transplant and before being accepted to undergo the procedure (Kotlyaar, 
2008). Also a reasonable familiar and social support is required. DiMartini et al. have proposed 
a selection method to identify alcoholic patients suitable for transplantation. Lucey et al 
have reported on a multidisciplinary collaboration of transplant hepatologists, surgeons and 
psychiatrists that identifies psychosocial predictors of long term sobriety and compliance 
after liver transplant in alcoholics (Weinrieb and Lucey, 2007; Dew, 2008). Pretransplant 
abstinence has two purposes; it allows a window of opportunity for the liver to stabilize (it 
is not exceptional that some cases have been withdrawn from the waiting list due to 
improvement), and it allows the opportunity to examine the patient’s commitment. 
5.3.1 Alcoholic Acute Hepatitis  
No systematic evaluation has been performed on patients transplanted for alcoholic liver 
disease (ALD). Data are limited on the impact of structured management of the alcohol 
problem on the risk of recidivism following transplantation in ALD. The question of a 
possible transplant during the acute episode remains unanswered. In these patients short 
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term survival is good after transplant. However, due to the relative scarcity of donors, the 
majority of transplant teams do not accept to list patients who are actively consuming 
alcohol. (Cowling, 2004), but it is controversial (Mathurin, 2011). 
5.4 Autoimmune and Cholostatic Liver Diseases 
Liver transplant is a well established therapy for patients with autoimmune hepatitis (AIH), 
primary biliary cirrhosis (PBC) or primary sclerosing cholangitis (PSC). The perceived QOL 
in patients with cholestatic liver disease before and after LT was measured using some 
aspects of QOL, including symptoms (pruritus, fatigue); physical, social, and emotional 
functioning; health perceptions (stigma); and overall QOL (Gross, 1999). Changes in these 
QOL parameters before and after LT were studied and also the relationships between 
clinical and QOL factors and was demonstrated that cholestatic liver disease displayed the 
best cost-effectiveness ratio after LT (Longworth, 2003). Following transplantation QOL was 
substantially better than before transplantation and there were no differences in QOL 
parameters between patients with AIH, PBC and PSC. Some authors have pointed out that a 
patient’s QOL 1 year after transplant could not be predicted by pre-transplantation QOL 
variables (Krasnoff, 2005; Bownik, 2009). 
5.5 Acute Liver Disease  
Acute liver failure continues to be associated with a high mortality rate, and emergency liver 
transplantation is often the only life-saving treatment (Riordan& Williams, 2003). Although, 
the short-term outcomes are worse in comparison with those for non-urgent cases, due to 
the initial recovery process, the majority of patients transplanted with acute liver failure, 
reported that they have a good quality of life (Sargent, 2007; Dobbels, 2010). The keys to 
long-term success and continued progress in urgent liver transplantation are the use of 
good-quality whole grafts and a short waiting list time, both of which depend on access to a 
sufficient pool of organ donors. In this group the pre-transplantation HRQOL data could not 
be assessed due to patients' clinical situation. However, there have been studies published 
reporting an acceptable survival and QOL., in the short or medium term (Chan, 2009).  
5.6 Issues related to HRQOL in receptors HIV+ 
More relevant problems at present are: - Primary disease recurrence, especially Hepatitis C 
virus, -Scarcity of donors, -Complications related to the chronic administration of 
immunodepressors (Tomé, 2008) The Spanish Liver Transplant Program for selected HIV+ 
carriers was initiated in 2002 due to the increasing burden of liver disease in patients with 
HIV (Joshi, 2011). Some new developments, both in the treatment of HIV+ and in the long-
term management of liver transplant recipients have enabled further improvement of the 
results. (Consensus conference, 2009). 
Studies are fragmented. Until recently different constructs and researches covered 1-2 years 
after transplantation and it is only now that there is a focus on the long term results. In acute 
liver failure a “better HRQOL related to shorter duration and lesser severity of liver disease” 
was observed. Disease recurrence has little impact on graft survival rates within 7-10 years 
of transplantation, in contrast, hepatitis C recurrent disease is an important concern in 
relation to survival and QOL (Holzner, 2001; Karam, 2003; Sainz-Barriga, 2005). 
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Survival of liver transplanted patients at five years depends on when the patients received 
liver transplant (K. Bjøro, 1999). In recent years, there has been considerable improvement in 
long-term clinical management and an increase in knowledge about risks, such as 
developing chronic renal disease, “de novo” tumours, primary disease recurrence etc. 
Present challenges are related to studies with a longer follow up, 10 to 20 years, some of 
which have been recently published (de Kroon, 2007; Ruppert, 2010).  
6. Indications of liver transplant and prioritization criteria on the waiting list 
When should a liver transplant be considered? There are medical and ethical concerns about 
the appropriate use of scarce resources, and the degree of priority given to patients with 
ALD has always been a controversial issue (Kotlyar, 2008). In recent years, approximately 
1200 liver transplants have been performed in Spain yearly. This means that on average 
three livers are received every day. 
Referrals to transplant centres should be made considering there is enough time to evaluate 
the candidate. Pretransplant evaluation and follow-up is a combined effort of clinicians, 
psychiatrists and substance abuse specialists. Assessment from medical, surgical and 
psychosocial points of view takes time and sometimes it can be like a race against time 
(Gutteling, 2007). Later referrals leave little scope to explore further medical management 
options or to allow time to work with the substance misuse or psychiatric team. Abstinence 
before transplantation evaluation and listing is important to select patients who would 
benefit the most from transplantation, as some would get better in this period (Drent, 2009). 
There should be reservations in listing patients with a lack of social support, active smokers, 
having psychotic or personality disorders, or a pattern of nonadherence.  
7. Studying QOL after liver transplant. Results in HCV, liver transplantation 
and QOL  
A review of quality of life instruments used in liver transplantation (Jay, 2009) has been 
recently published. Factors influencing the QOL of an individual patient include 
pretransplant disease severity, complications during the perioperative period, long-term 
adverse effects of immunosuppressive drugs, the etiology and recurrence of the underlying 
liver disease and the information received from the medical team throughout the process 
(Paterson, 2000).  
Nowadays, liver transplantation is a common therapeutical option. However transplantation 
teams have to deal with strict selection of candidates, due to the relative shortage of donors. 
Moreover we have to take into consideration the present available information on the 
natural history regarding the risks of “de novo” diseases, or malignancy or the primary 
disease recurrence in the long term (Telles-Correia, 2011; Estraviz, 2007). Other goals may be 
more widely accepted, for example, describing functional health and HRQOL before and 
after transplantation; comparing contrast outcomes and exploring whether physiological 
performance, demographics, and other clinical variables are predictors of post-
transplantation QOL (Bravata& Keeffe, 2001; Ho, 2006; Aberg, 2009). 
In particular, HCV-infected patients generally report a worse QOL before transplant and a 
lesser increase in QOL after transplant than patients transplanted for other reasons (Feurer, 
2002). 
www.intechopen.com
 
Liver Transplantation – Basic Issues 
 
174 
The major predictors of poor adherence to medication gives an idea of how we can 
intervene early in treatment (Bernstein, 2002). There are few studies addressing QOL in 
relation with anti-HCV treatment after liver transplant (Alsatie, 2007; Neri, 2010). Patient 
and treatment factors to be aware of are treatment of asymptomatic disease; the presence of 
psychological problems, particularly depression; a patient’s lack of belief in the benefit of 
treatment; the complexity of the treatment; and adverse events (Schiano, 2006). Other factors 
that perhaps are harder to quantify are a poor provider-patient relationship, inadequate 
follow-up or discharge planning, missed appointments, and the cost of medication, 
copayment, or both. (Ghobrial, 2001). 
Liver transplant recipients do not, however, achieve the same QOL scores as healthy 
controls, and the prevalence of psychiatric comorbidities including depression is higher than 
controls (Dew, 1997). Patients experience more acute anxiety and depression, especially ex-
alcoholics and hepatitis C patients (Paterson, 2000). 
Despite few physical manifestations of disease at the time of HCV recurrence, patients report 
an impaired quality of life and functional status compared with other recipients without 
recurrence (Feurer, 2002). This suggests that patient knowledge of the diagnosis of recurrent 
HCV alone can negatively impact HRQOL (Hauser, 2004). They perceive themselves as 
unwell and have significant changes in their mental and physical health despite the absence 
of disease-related complications. However, only a limited number of studies have 
investigated the influence of gender, HCV genotype, or HCV antiviral treatment on the 
HRQOL of liver transplanted patients with HCV recurrence (Feurer, 2002; Saab, 2010).  
Complexity of the treatment requires an extra effort by the transplant team, for example 
before patients leave the hospital after transplant. Adverse events of medication have to be 
taken into account, possibly in the long-term, due to poorer physical functioning, 
depression, and greater rates of fatigue some patients can miss some doses. More than 50% 
of liver transplants recipients survive more than 20 years, achieve important self-
achievements, and report quality of life superior to patients with liver disease or other 
chronic conditions (Ruppert, 2010).  
8. Clinical relevance of measuring QOL and methodological difficulties 
Liver transplant is a surgery that restores both long-term physiology and well-being in 
patients with end-stage liver disease. (Tomé, 2008) Factors that have to be considered 
include the stress of waiting for a liver transplant - with its uncertainty in terms of both 
timing and outcome - as well as the physical and psychological demands of the procedure in 
the pre- and post-transplant period (Goetzmann, 2006). Other demands on the long term are 
linked to general quality of life (QOL) and treatment adherence (Drent, 2009). 
It is necessary to differentiate the clinical situation of patients with acute liver disease versus 
those with chronic liver disease, due to the process of adaptation that usually happens in 
chronic diseases. Several cross-sectional and longitudinal studies show a statistically 
significant increase in QOL after transplantation in the majority of patients. Longitudinal 
studies are preferable to cross sectional studies. 
Capture of the HRQOL experiences across disease severity and etiology of the liver disease 
is challenging because of subtle differences in the disease and the background of the person  
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(Norman, 2003). Post-transplantation HRQOL scores are not affected in general by the 
etiology of the original liver cirrhosis, but transplant recipient scores continue to remain 
significantly lower than those of healthy patient controls. Prospective studies, showing the 
QOL evolution in the long term follow up, are starting to show differences between the 
cause of transplant and clinical evolution (Ruppert, 2010). Minimal clinical important 
difference is a concept defined as the minimal change in HRQOL which is important for the 
patient, allowing patients to report a minimal yet perceptible change in their health 
(Norman, 2003). Confirmation of the preliminary results in this group of patients is 
necessary. 
Relapse of substance abuse, especially alcohol consumption, often affects not only QOL, but 
also adherence to immunosuppressive therapy and thus long-term survival after OLT. As 
relapse of alcohol addiction occurs in 10 to 30% of OLT recipients, continuous psychological 
support has an important role in post-transplant care (Pfitzmann, 2007). 
The risk of recurrent disease in the graft influences the clinical prognosis. In previous 
alcoholics, or other addicts, disease recurs in a minority of patients. For example, in 
alcoholic disease histologically proven disease recurrence is not frequent whereas it is the 
rule in hepatitis C, and is not common in cases of primary biliary cirrhosis, auto-immune 
hepatitis, or primary sclerosing cholangitis (Kotlyar, 2006). 
In addition to being influenced by the psychological and physical condition of the patient, 
QOL is also affected by social function and occupational activity. Employment rates in liver 
transplanted recipients depend on several factors, such as age, education, duration of their 
disability and country. The number of patients returning to work after transplant ranges 
from 30% in Germany to about 55% in the United States and Canada (Bravata, 2001; Aberg, 
2009). 
During the first 6 months after liver transplantation, the majority of physical and mental 
components of health-related quality of life scores improve, but these increases are not 
sustained in the long term (De Bona, 2000). At 1 year after liver transplantation, emotional 
and mental health-related quality of life scores are balanced with a tendency to decrease 
(Paterson, 2000). In the postoperative years 1 to 5, possible episodes of acute cellular 
rejection, recurrent disease and patient age over 60 years decrease physical function and 
overall general QOL scores (Levy, 1995). Beyond 5 years after liver transplantation, 
osteoporosis, and episodes of chronic rejection may decrease QOL scores through decreases 
in the physical function and bodily pain domains (Karam, 2003). 
9. The importance of psychological aspects 
With regard to psychopathology, it is important to note that it is not always a 
contraindication for transplant per se (Jowsey, 2001; Gutteling, 2010). Some studies however, 
show that psychiatric diagnosis is common among transplant candidates specially in 
patients with previous alcoholic liver disease and hepatitis C carriers who may have worse 
clinical outcome after transplantation (Sherman, 2004).  
Telles-Correia, et al, found that in the pre-transplant period, the prevalence of depression 
was observed in 33% of patients, anxiety was observed in 34%, and dependency on alcohol 
or drugs was observed in 59%. After transplant, depression prevalence was observed in 
30%, anxiety in 26%, and psychosis in 6.4% (Telles-Correia, 2006). 
www.intechopen.com
 
Liver Transplantation – Basic Issues 
 
176 
As we mentioned above, non-adherence before transplantation is predictive of non-
adherence after transplantation. It is known that anti hepatitis C virus viral treatment is 
associated with neuropsychiatric side effects (Quelhas,& Lopes, 2009). Therefore, in these 
situations, psychopharmacological treatment is required to be initiated as soon as possible, 
especially in patients with a history of psychiatric disorder, to assure adherence to 
medication (Gangeri, 2007; Quelhas & Lopes, 2009). Many factors may affect the process of 
adaptation to the disease (Kendall; 1995; Uchino, 1996; Telles-Correia, 2008). Patients can 
have different coping strategies, the most common being, stoic acceptance, denial, 
hopelessness, anxious concern and fighting spirit.  
Coping strategies may change over time, depending on specific stressors and the development 
that follows the disease. Studies show that fighting spirit and denial are ways of coping better 
than the rest, in the sense that facilitate adjustment to illness (Carver, 2005; Russell, 2008). 
9.1 Psychosocial aspects in family and advanced liver disease  
Emotions are stressful for the patient and also for the family and can lead to physical and 
emotional exhaustion (Nickel, 2002). Family members usually have emotional troubles, 
sometimes overlapping those presented by the patient. The most common are: fear, anxiety, 
sleep disturbances, difficulty concentrating, loss of appetite, and fatigue (Sanders, 2008). 
When the patient gets all the attention, a feeling of isolation among other family members 
may appear (Pérez San Gregorio, 2008; Stilley, 2010). Moreover, other perceptions have been 
observed, such as guilt, when the patient is left alone, or fear of not doing enough or not 
doing something correctly, etc..,  
It is also important to mention two phenomena that may affect the whole family, and they 
are: the conspiracy of silence and family claudication (Miyazaki, 2010). The conspiracy of 
silence attempts to prevent that the parties involved become aware of the diagnosis and 
prognosis of the disease. The results are the emergence of mistrust, isolation, limited 
emotional expression and isolation which can create family-physician-patient misleading 
relationships (Bolkhir, 2007). To avoid the conspiracy of silence we must always take into 
account the real needs and desires of the patient information that can change with the time 
(Carr, 2001). 
Family claudication: expresses the absence of the family’s ability to respond adequately to 
the demands and needs of the patient due to a state of exhaustion and an overwhelming 
feeling that results in difficulties in maintaining a positive communication between the 
patient, family members, and the healthcare team (Szeifert, 2010; Kramer, 2011). 
9.2 Psychosocial intervention in patients with advanced liver disease 
The role of the psychological assessment and monitoring during the pre-and post-transplant 
phases, has been recognized. Identifying and reducing psychological risk factors may play a 
role in the long-term success of transplantation (Crone, 2006). 
Previous studies suggest that psychological intervention during the process of hepatitis C 
disease and transplantation is important and necessary (Quelhas &Lopes, 2009). Emotional 
support during the illness, before and after transplantation, both individually or in groups, 
can improve the emotional well being, HRQOL, survival, facilitate the adaptation and 
adherence of transplant candidates and transplant patients (Knott et al. 2006; Quelhas & 
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Lopes, 2009; Steel, 2007). The goals of psychological intervention are to improve the QOL in 
patients with liver disease, facilitating their adaptation to the disease, accepting adaptive 
coping strategies and ultimately improving the patient's sense of self-control (Goetzmann et 
al, found in a sample of 69 patients, that almost half (47%) expressed the need for emotional 
support during the assessment for the procedure of liver transplantation (Goetzmann, 2007).  
Van den Plas et al., showed that for transplant patients psychological support in the pre-and 
post-transplant periods besides the rehabilitation provided by the medical and nursing team 
and family, were one of the essential aspects of the transplant program (Van den Plas, 2003). 
In mood disorders and anxiety disorder, psychopharmacological therapy in conjunction 
with psychotherapy may ameliorate the disturbance to the point at which patients can reach 
an emotional, and affective balance. Their equilibrium, allows them to manage the eventual 
distress related to the transplant (Crone, 2006). Such patients, however, need constant 
support before, during and after transplantation; during the pre-transplantation phase, 
specifically for sensitivity to stress, (Table 6) and in the post-transplant phase, most 
significantly because of immunosuppressant therapy that might precipitate mood swings, 
irritability, mania and anxiety. Psychotherapy and/or psychotherapy in conjunction with 
pharmacological treatment might be indicated during all the phases of the transplant 
process as they are individuals who tend to manifest traits such as depression, anxiety and 
phobia (Marcellin, 2007). Anxiety reduction techniques, autogenic training, systematic 
relaxation techniques, guided imagery, and pain management are recommended (Pasquini, 
2006; Pelgur, 2009). 
Informed consent  Personality profile  Psychopathology 
Past/present psychiatric history  Effect of illness on daily life activities 
Use/abuse of alcohol and/or drugs 
Defense mechanism employed and coping skills 
Motivation for surgery  Treatment compliance 
Perceived Quality of Life  Support from the family and friends 
Socioeconomic support (together with nurses team and social worker’s evaluation) 
Awareness of information regarding the actual surgical event and future treatments 
Table 6. Domains of the pre-transplant psychological evaluation 
A mail survey was done to assess the importance of professionals assigned to psychosocial 
factors in evaluations for liver transplant candidacy and liver transplant surgeons from the 
highest volume liver transplant centers in the United States. Psychosocial evaluators 
assigned greater importance to availability of transportation, adaptation to stress and coping 
skills and were less likely than transplant surgeons to recommend that a patient with a 
history of poor social support be listed for liver transplant. The results of the study showed 
that factors identified by psychosocial evaluators are important and transplant outcomes 
should be studied (Santos Junior, 2007). 
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10. Experiences in our unit 
Our Liver Transplant Unit started the liver transplant program in 1984. In 1987 we began to 
study QOL using the generic test NHP (Figueras, 1989). Interestingly, this test allowed us to 
confirm that after one year of having received transplant, alcoholic patients showed a 
recovery in all questions related to their daily life. Their recuperation was similar to that of 
female patients transplanted for primary biliary cirrhosis. Our explanation was that ex-
alcoholics, recipients of transplantation, not only resolved their medical problems while 
abstaining from alcohol but also experienced a global improvement and had better self-
esteem. In our experience patients are offered a new outlook on life post-transplant. Even 
patients who are suffering from self-inflicted damage (ex-alcoholics or ex-drug users) 
perceive the donation as proof of solidarity, which sometimes results in them strengthening 
their relationships with family and friends and in some cases, renewing past relationships. 
Congress of Spanish Liver Transplantation Groups (1992 Murcia), lecture’s main focus was 
to discuss the "QOL after liver transplant” and whether the etiology of alcohol could affect 
in the results. It is interesting that we have detected some ex-alcoholics who are riskier cases. 
They have to attend regular visits with the psychiatric team. After liver transplant some 
patients may relapse and return to alcohol use. Rehabilitation in these cases is also possible. 
In our experience, severe cases are the exception; younger males (under 50 years old) who 
have shown a strong tendency to relapse and who have presented severe cases of 
recidivism, with small likelihood of rehabilitation.  
After 2000, due to the relevance of the use of a specific disease questionnaire for QOL 
assessment in clinical liver diseases and liver transplantation settings, we started using the 
LDQOL questionnaire, which was translated and adapted to the Spanish population by our 
group (Casanovas, 2003; 2007).  
We then made correlations with clinical and analytical data pre and post-transplant, and 
with validation and outcome studies (Casanovas, 2010a). The administration of this long 
questionnaire is time consuming. We are therefore currently planning to administer the SF- 
LDQOL questionnaire, which has already been validated by its authors ( Kanwal, 2008). 
Recently, some research on QOL in patients with chronic liver disease, with or without 
HCC, awaiting liver transplantation and the sensitivity to change of the LDQOL 
questionnaire to determination of the quality of life of liver transplanted patients 
prospectively followed for twoyears, has been presented. 
The LDQOL 1.0 has proven to be a useful and valid tool for measuring QOL cross-
sectionally in patients with liver disease. However, its sensitivity to change, or capacity to 
reflect actual changes in QOL after an intervention of assumed effectiveness, has not been 
studied to date. Studies on sensibility to change assessed using a prospective follow up from 
baseline, before transplant to 2 years after transplant, were presented at the AASLD meeting 
(Casanovas, 2010 b). 
11. Recommendations for future QOL after liver transplant studies 
Areas of future research related to QOL might help to settle long term problems associated 
with liver transplantation. There are a number of reliable and valid instruments, however 
none of them can be considered as the gold standard outcome to be used in all situations. 
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In future studies, more attention should be paid to the QOL outcomes in liver transplant 
recipients with alcoholic liver disease, hepatocellular carcinoma and those with hepatitis C. 
Some articles also suggest that female liver transplant recipients should receive special 
attention (Russell, 2008).  
Others point out the importance of focusing on the recovering functions both during the 
initial period post-transplant and on the long term results. How the new available 
immunosuppressor drugs have to be adjusted will depend on further research incorporating 
HRQOL results. (Crone, 2006) 
In relation to patients with previous addictions, there is no definitive biochemical test to 
identify alcohol relapse and the tests available have poor sensitivity and specificity, so 
emphasis on QOL is also important. More research is required in this field to detect alcohol 
ingestion before it has an effect on the new liver or when social and familiar behaviour 
could be difficult to manage. (Stilley, 2010) 
More attention for caregivers, usually wives because men are more frequently affected by 
liver diseases, is required. In single patients, it is necessary to identify a circle of friends or 
other family members who are willing to support and take care of them. (Carver, 2005; Day, 
2009; De Blesser, 2009). 
Considering factors that could condition differences in the evolution, future researches 
should assess a larger number of cases than those done to date,and implement prospective 
studies. 
12. Conclusion 
In the last few years, it has been recognized that incorporating the patient’s perspective on 
the outcomes of interventions is highly important. While the impact of a health condition on 
an individual is reflected by symptoms and altered functions, these reflect only part of the 
total impact of a disease, hence the need to capture the effects on perceptions of his/her self 
well-being. Moreover, the ratings of physicians on the presence or absence and severity of 
symptoms or functional limitations can differ from patients’ ratings and even from person to 
person. 
Among the measures representing the health effects from the perspective of the patient, are 
validated questionnaires of HRQL and QOL. Three content areas are crucial, symptoms, 
functions, and well-being. There are well developed psychometrically generic and disease 
specific indices suitable for particular areas of research or practice. Chronic liver disease 
patients perceived a lower measured HRQOL, compared to other chronic disease patients, 
especially those with advanced or decompensated liver disease. 
The results of QOL studies help the physicians to have a better understanding of chronic 
liver disease patients, some of them candidates to transplantation others post-transplant, 
thus enabling them to provide their patients with better support. Recognizing the goal of 
restoration of maximal QOL is essential to create appropriate interventions and to have the 
required information in order to improve treatment adherence and provide more overall 
satisfaction with QOL after liver transplantation. 
In clinical trials, evaluating new drugs or new treatment schedules, quality-of-life 
questionnaires should always be added to the usual criteria of toxicity, efficacy or other 
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evaluations. Liver transplant outcomes have to be considered as both a life-saving 
intervention and also as an opportunity to improve QOL. Patient interests –reported QOL- 
should suggest opportunities for ongoing development and research in this area. Therefore, 
we conclude that psychological care should be offered in all health centers and included in 
the comprehensive care of patients with liver disease. 
More research into the predictive and ethical aspects of psychosocial evaluation for liver 
transplant is needed. Further studies are necessary that include a complete evaluation of the 
effects of gender, age, socioeconomic status, education, and ethnicity in order to understand 
modifiable factors on HRQOL especially after HCV recurrence in transplanted patients that 
could greatly improve patient’s QOL with specific interventions. 
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